Jerry Ainsworth, MD
Psychiatry · Monterey, CANPI 1720099427
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 879 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 33.1% of the total. Reporting peaked in 2019 at $3,577 and has fallen 80.4% since, to $700 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 879 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Johnson & Johnson$2K
- Sunovion Pharmaceuticals Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$841
- Teva Pharmaceuticals USA, Inc.$683
- plus $4K from 22 others
What the payments were for
- Food & beverage$14,84099%
- Education$1221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 265 | $4,960 |
| Johnson & Johnson | 129 | $1,760 |
| Sunovion Pharmaceuticals Inc. | 77 | $1,486 |
| Otsuka America Pharmaceutical, Inc. | 115 | $1,449 |
| Alkermes, Inc. | 35 | $841 |
| Teva Pharmaceuticals USA, Inc. | 33 | $683 |
| Lundbeck LLC | 67 | $581 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $579 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $394 |
| Merck | 18 | $371 |
| Avanir Pharmaceuticals, Inc. | 17 | $362 |
| Axsome Therapeutics, Inc. | 7 | $254 |
| Neurocrine Biosciences, Inc. | 12 | $248 |
| Eisai Inc. | 15 | $183 |
| Vanda Pharmaceuticals Inc. | 6 | $137 |
| Indivior Inc. | 6 | $118 |
| Jazz Pharmaceuticals Inc. | 5 | $113 |
| Tris Pharma Inc | 5 | $94 |
| Idorsia Pharmaceuticals US Inc | 4 | $83 |
| Ironshore Pharmaceuticals Inc. | 4 | $66 |
| Boston Scientific | 2 | $39 |
| Neuronetics, Inc. | 1 | $38 |
| Shire North American Group Inc | 2 | $33 |
| Neos Therapeutics, LP | 2 | $28 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Bausch Health US, LLC | 1 | $16 |
| Corium, LLC | 1 | $12 |
| Adlon Therapeutics L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,962 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 30 | $41,324 |
| Abilify MaintenaAripiprazole | 13 | $29,280 |
| TrintellixVortioxetine Hydrobromide | 18 | $16,631 |
| Modafinil | 18 | $16,208 |
| Lurasidone Hcl | 20 | $6,269 |
| Quetiapine Fumarate | 63 | $2,239 |
| Gabapentin | 118 | $2,205 |
| Olanzapine | 39 | $1,372 |
| Bupropion XlBupropion Hcl | 63 | $1,345 |
| Aripiprazole | 33 | $1,131 |
| Trazodone Hcl | 87 | $1,011 |
| Buspirone Hcl | 47 | $988 |
| Fluvoxamine Maleate | 18 | $909 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $831 |
| Duloxetine Hcl | 28 | $827 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $4,960 | $41,32430 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,449 | $29,28013 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $579 | $16,63118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Monterey
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.